Cogent Biosciences Stock Investor Sentiment

COGT Stock  USD 7.39  0.14  1.93%   
Slightly above 79 percent of all Cogent Biosciences' private investors are aggressively thinking of buying. The analysis of the overall investor sentiment regarding Cogent Biosciences suggests that a fairly large number of traders are excited. Cogent Biosciences' investing sentiment can be driven by a variety of factors including economic data, Cogent Biosciences' earnings reports, geopolitical events, and overall market trends.
  

Cogent Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cogent Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at news.google.com         
Cogent Biosciences Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Google News at Macroaxis
3 days ago at finance.yahoo.com         
Is Cogent Biosciences, Inc. a Best Biotech Stock According to Billionaires?
Yahoo News
over a week ago at news.google.com         
Scotiabank Initiates Coverage of Cogent Biosciences with Sector Outperform Recommendation - Nasdaq
Google News at Macroaxis
over a week ago at gurufocus.com         
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Cogent Biosciences, Inc. Shares Sold by Fisher Asset Management LLC
news
over two weeks ago at news.google.com         
When the Price of Talks, People Listen - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in ...
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdv...
Macroaxis News: globenewswire.com
over three weeks ago at globenewswire.com         
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financia...
Macroaxis News: globenewswire.com
over three weeks ago at gurufocus.com         
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 ...
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Cogent Biosciences Reports Q4 2024 Net Loss of 67.9 Million, Exceeds EPS Estimate of -0.59
Gurufocus Stories at Macroaxis
over three weeks ago at news.google.com         
Long Term Trading Analysis for - Stock Traders Daily
Google News at Macroaxis
over a month ago at gurufocus.com         
Steven Cohens Recent Transaction with Cogent Biosciences Inc
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
FY2025 EPS Forecast for Cogent Biosciences Raised by Analyst - MarketBeat
Google News at Macroaxis
over a month ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Cogent Biosciences Shares
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Cogent Biosciences that are available to investors today. That information is available publicly through Cogent media outlets and privately through word of mouth or via Cogent internal channels. However, regardless of the origin, that massive amount of Cogent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cogent Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cogent Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cogent Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cogent Biosciences alpha.

Cogent Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Cogent Biosciences, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat
12/20/2024
2
Acquisition by Ferrante Karen Jean of 2785 shares of Cogent Biosciences at 7.8 subject to Rule 16b-3
12/31/2024
3
Acquisition by Pinnow Cole of 43750 shares of Cogent Biosciences at 7.598 subject to Rule 16b-3
01/14/2025
4
Acquisition by Kearns Evan of 230000 shares of Cogent Biosciences at 8.89 subject to Rule 16b-3
01/23/2025
5
Cogent Biosciences Trading Up 7.3 percent - Still a Buy - MarketBeat
01/24/2025
6
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
01/30/2025
7
Short Interest in Cogent Biosciences, Inc. Expands By 9.3 percent - MarketBeat
02/05/2025
8
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis at the 2025 AAAAI Annual Meeting
02/10/2025
9
FY2025 EPS Forecast for Cogent Biosciences Raised by Analyst - MarketBeat
02/13/2025
10
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 ...
02/25/2025
11
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in ...
02/27/2025
12
Cogent Biosciences, Inc. Shares Sold by Fisher Asset Management LLC
03/06/2025
13
Is Cogent Biosciences, Inc. a Best Biotech Stock According to Billionaires
03/17/2025

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.